معرفی
Torbjörn Gräslund is a Professor of Medical Protein Technology at KTH Royal Institute of Technology. His work focuses on designing protein-based molecules for medical applications, particularly in cancer therapy and diagnosis. His research group develops drug conjugates targeting HER2 and EpCAM receptors, with an emphasis on minimizing healthy tissue impact while maximizing tumor efficacy.
Key research areas include the development of targeted toxins, pretargeting strategies for cytotoxic drug delivery, and optimizing radiolabeling techniques for PET and SPECT imaging. He explores molecular design principles to enhance drug conjugate half-life and tumor uptake through albumin-binding domains (ABD) and protein fusion technologies.
His articles highlight advancements in HER2/HER3-targeted therapies, albumin-binding domain applications, and novel imaging probes for oncological diagnostics. Collaborations involve interdisciplinary projects combining protein engineering with preclinical testing in mice models.
Notable research contributions include the evaluation of Affibody molecules as therapeutic and diagnostic agents, and the use of designed proteins like DARPins for EpCAM imaging in pancreatic and prostate cancers. No scientific awards or grants are explicitly mentioned in the provided texts, though his extensive publication record indicates impactful work.
